Not just any mentor, but the right mentor, can be a boon to your success and business. A poor one can trip you up just as any other potential pitfall in the path to your success. So look for:
1) A person who is in your industry with a proven track record, complete with client testimonials you can check out, products / services with examples to share with you and an executive resume for your consideration.
2) Someone with reasonable instructions for you as a mentor and contact information that works and works well for both of you. In short, don't get someone with only a Support Desk link who rarely, if ever, replies to it. You want tried and proven communications, emails that get responses, phone calls, etc.
3) Someone with a mentoring program targeted for what you want to accomplish, in your time frame and in your budget range. In short, you don't need someone to fly a man to the moon, when you don't need all that technology, time, energy and money spent there. You want someone who can help you with your short list and long list of goals, in a timely manner and in your budget range.
4) A commitment with check points all along the way, and no long-term contract you cannot get out of. In short, month to month programs work well, but annual ones of 5-figures and more are not good for beginners.
Start small and see how your mentoring works out for a month. See if you get anything worthwhile accomplished. Then grow with your mentor, tackling larger and more expensive project tasks as they come up, even doing joint ventures together down the road.
Find a Mentor
There are many ways to find the right mentor. Popular ways are:
a) In industry newsletters and other offline publications. Ask your local librarian to help you locate print magazines, newsletters and other timely publications in your niche. Then check ads in them and on their company website, especially look for classified ads.
b) Seek industry forums, blogs, ezines and other online publications. Open Google in your web browser or other popular search engine, and type in "your niche + forum" or "your niche + blog" to get a list going of sites to check out. Popular ones often have blogs on them at the folder's domain + /blog or /forum files; for example: MyWebsite.com/blog or MyWebsite.com/forum.
c) Ask your friends and business associates for recommendations. Many are happy to share their resources, programs, contacts and trusted mentors with you. Share any with them, too.
Once you do get ahead, don't forget to give back. You may be called upon to mentor others coming up in the industry!
Nektar Therapeutics (NASDAQ:NKTR) announced today the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Amphotericin B Inhalation Powder (ABIP) for prevention of pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy, including those receiving organ or stem cell transplants, or treated with chemotherapy or radiation for hematologic malignancies (leukemias).
The FDA granted Fast Track designation for the following reasons:
-- Invasive aspergillosis is a serious infection that usually affects immunosuppressed patients receiving organ or stem cell transplants, or treated with chemotherapy or radiation for hematologic malignancies. The infection is often lethal in medically immunosuppressed patients.
-- There is no approved agent for prevention of pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy, including those receiving organ or stem cell transplants, or treated with chemotherapy or radiation for hematologic malignancies. Therefore, there is an unmet medical need for a new treatment.
Fast Track designation allows the FDA to expedite the review of new drugs that are intended for serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. An important feature of Fast Track designation is that it emphasizes the critical nature of close, early communication between the FDA and the sponsor company to improve the efficiency of product development. Under Fast Track, Nektar is now eligible to submit portions of the marketing application for review on a rolling basis prior to completion of the final registration package for the product.
"We are pleased that the FDA recognizes that Nektar's product for this indication meets the criteria for Fast Track designation and this is an important step toward providing a much-needed medical solution to protect against life-threatening pulmonary infections," said Dr. David Johnston, Nektar senior vice president of research and development. "Our product could represent a major paradigm shift in antifungal therapies as we aim to prevent infections by targeting the lungs directly and therefore avoid the serious systemic and dose-limiting side effects of intravenous and oral therapies. We look forward to working closely with the FDA through the development process."
Nektar announced in February 2006 that the FDA had granted U.S. orphan drug designation to ABIP for the prevention of pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy. The Orphan Drug Act provides a seven year period of exclusive marketing to the first sponsor who obtains marketing approval for a designated product for the designated indication.
About Amphotericin B Inhalation Powder (ABIP)
ABIP is under development for the prevention of pulmonary aspergillosis in high-risk immunosuppressed patients. The product is designed to target the site of infection directly with a novel formulation of amphotericin B, a broad spectrum, "gold-standard" antifungal drug. Nektar's innovative formulation and pulmonary delivery method could potentially eliminate systemic, dose-limiting toxicities found with current formulations of amphotericin B that are delivered intravenously.
Immunosuppressed patients -- i.e., those receiving organ or stem cell transplants, or chemotherapy or radiation therapy for hematologic malignancies -- are vulnerable to opportunistic fungal infections, such as aspergillosis, which start in the lungs and spread throughout the body. Aspergillosis has a mortality rate of over 50%, and in some immunosuppressed patient groups the mortality rate may be as high as 100%.(1) Using ABIP for patients at risk of developing the infection may potentially reduce the incidence of these infections, as well as associated high morbidity and mortality and significant treatment costs.
ABIP is currently in a multidose Phase I study. In February and March of 2006, encouraging pre-clinical and Phase I data on ABIP were presented at major scientific congresses, including the 2nd Advances Against Aspergillosis Meeting and Focus on Fungal Infections 16th Annual Meeting. In December of 2005, data on ABIP was also presented at the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy.
Both Roy Carter & Dave Gosine are contributors for EditorialToday. The above articles have been edited for relevancy and timeliness. All write-ups, reviews, tips and guides published by EditorialToday.com and its partners or affiliates are for informational purposes only. They should not be used for any legal or any other type of advice. We do not endorse any author, contributor, writer or article posted by our team.
Roy Carter has sinced written about articles on various topics from A Secured Loan, Brain Tumor and Management Software Solutions. Roy Carter has now taught hundreds of people all over the world how to make an automatic income online. He now offers his 1 Year Internet Marketing. Roy Carter's top article generates over 33100 views. Bookmark Roy Carter to your Favourites.
Dave Gosine has sinced written about articles on various topics from Health, Internet Marketing and Mazda. Webbolt (webbolt.ecnext.com/coms2/description_60922_Nektar060606_MED), provides an on-demand, dynamically presented, tailored, tot. Dave Gosine's top article generates over 74000 views. Bookmark Dave Gosine to your Favourites.